Members

LSCLogo.gif


Task Force Members
March 2011

Oren Cohen, Quintiles Transnational
Gregory Curt, AstraZeneca
Christine Dingivan, PPD
James Doroshow, National Cancer Institute
Ana Maria Garcia, sanofi-aventis
Richard Gaynor, Eli Lilly
Martine George, Pfizer
Allicia Girvan, Eli Lilly
William Hait, Johnson & Johnson
Roger Herdman, Institute of Medicine
Charles Hugh-Jones, sanofi-aventis
Svetlana Kobina, sanofi-aventis
Viren Mehta, Mehta Partners
Martin Murphy, CEO Roundtable on Cancer
Sharyl Nass, Institute of Medicine
Paolo Paoletti, GlaxoSmithKline
Phillip Porter, Hogan Lovells  
Sheila Prindiville, National Cancer Institute
Wayne Rackoff, Johnson & Johnson
Mace Rothenberg, Pfizer
Debasish Roychowdhury, sanofi-aventis
August Salvado, Novartis
Josh Schafer, US Astellas
Ira Steinberg, sanofi-aventis
Dan Sullivan, H. Lee Moffitt Cancer Institute
John Wagner, Merck


Standard Terms of Agreement for Research Trial (START) Clauses

StartCover.png Access to standardized legal language for Key elements can increase the efficiency of contract negotiations, resulting in reduced costs and accelerating the entry of new therapies into clinical trials.

Print Page Email Page to Friend Feedback
© 2012 by Life Sciences Consortium  All rights reserved.